One of the most notable drugs that recently lost its US exclusivity was Abbvie’s Humira. Humira generated $18.62 billion in US sales in 2022. Others expected to join them this year are Johnson & Johnson’s Stelara, $6.39 billion US sales in 2022, Takeda’s Vyvanse, $2.53 billion US sales in 2022, Sanofi’s Aubagio, $1.5 billion US sales in 2022 and Roche’s Actemra, $1.2 billion US sales in 2022.
Click here to see the complete list.